Search - tctmd.com

Displaying 21 - 40 of 210

Sort: Relevancy | Date

News Daily News

‘Accelerated Atherosclerosis’ Not Uncommon in Arteries of Young People

Caitlin E. Cox

November 15, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

L.A. McKeown

November 15, 2018

News Conference News AHA 2018

Long-term FREEDOM: At Nearly 8 years, CABG Maintains Mortality Benefit Over PCI

Michael O'Riordan

November 14, 2018

News Conference News AHA 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Caitlin E. Cox

November 13, 2018

News Conference News AHA 2018

Sit Less, Move More: New Physical Activity Guidelines Stress Movement at All Ages

Michael O'Riordan

November 12, 2018

News Conference News AHA 2018

Very EARLY Invasive Angiography in NSTE ACS Patients Reduces Risk of Recurrent Ischemia

Michael O'Riordan

November 11, 2018

News Conference News AHA 2018

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Shelley Wood

November 11, 2018

News Conference News AHA 2018

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

Todd Neale

November 10, 2018

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

Todd Neale

November 10, 2018

News Conference News AHA 2018

VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer

Shelley Wood

November 10, 2018

News Daily News

Lower Hypertension Range Tied to Heightened CVD Risk in Younger Adults

Todd Neale

November 08, 2018

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

News Daily News

Low Incidence of A-fib Seen in Elite Athletes, Including Runners and Triathletes

Michael O'Riordan

November 02, 2018

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Daily News

Higher Fitness Again Tied to a Lower Risk of Death, Including CVD Mortality

Michael O'Riordan

October 30, 2018

News Features

Country Roads: Vulnerable West Virginia Heart Patients Targeted in Outreach Program

Michael O'Riordan

October 29, 2018

News Daily News

Benefit-Based Approach to Statins Pinpoints One in Six Patients Eligible for Therapy

Michael O'Riordan

October 25, 2018

News Daily News

Health Forecast for 2040: Improved Life Expectancy for Most, but Troubling Trends Ahead

L.A. McKeown

October 24, 2018

Advertisement

‘Accelerated Atherosclerosis’ Not Uncommon in Arteries of Young People

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

Long-term FREEDOM: At Nearly 8 years, CABG Maintains Mortality Benefit Over PCI

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Sit Less, Move More: New Physical Activity Guidelines Stress Movement at All Ages

Very EARLY Invasive Angiography in NSTE ACS Patients Reduces Risk of Recurrent Ischemia

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer

Lower Hypertension Range Tied to Heightened CVD Risk in Younger Adults

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Low Incidence of A-fib Seen in Elite Athletes, Including Runners and Triathletes

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Higher Fitness Again Tied to a Lower Risk of Death, Including CVD Mortality

Country Roads: Vulnerable West Virginia Heart Patients Targeted in Outreach Program

Benefit-Based Approach to Statins Pinpoints One in Six Patients Eligible for Therapy

Health Forecast for 2040: Improved Life Expectancy for Most, but Troubling Trends Ahead

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content